Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GGH | Q92820 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72230 | 1.00 | ACE (0.48) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL11225236 | 0.84 | ACE (0.46) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL16575627 | 0.82 | GGH (0.48) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL16575628 | 0.82 | GGH (0.48) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL16575618 | 0.82 | GGH (0.48) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL21418523 | 0.80 | MMP1 (0.34) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL22300378 | 0.79 | TP53 (0.36) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL17859365 | 0.77 | MMP1 (0.37) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL19300637 | 0.77 | MMP1 (0.37) | ACEMMP1MMP8CA12CA1 | |
| SCHEMBL12257201 | 0.77 | LTA4H (0.41) | LTA4HLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617818-B2 | Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them | UNIVERSITY OF NORTH TEXAS (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260062449-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ONL THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260049106-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ONL THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3365354-B1 | PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT | CANBAS CO LTD (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034223-A1 | BIOMIMETIC EXTRACELLULAR MATRIX NANOFIBERS ELECTROSPUN WITH CALRETICULIN | NEW YORK UNIVERSITY (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4673477-A1 | CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS AND CONSTRUCTS INCORPORATING SAME | BioAtla, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12473360-B2 | Multi-specific antibody constructs | BIOATLA, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4565595-A2 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ONL Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4565596-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ONL Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250114429-A1 | VISTA ANTAGONIST AND METHODS OF USE | KING S COLLEGE LONDON (GB) | 2025-04-10 | — | — | US | disclosed |
| EP-0745095-A1 | PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5508384-A | NEUROLEPTIC AGENTS WITH REDUCED SIDE EFFECTS | NEW YORK UNIVERSITY (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995022561-A2 | PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1995-08-24 | — | — | WO | disclosed |
| WO-1995020397-A1 | PHOSPHACAN, NUCLEIC ACIDS ENCODING THEREOF AND ANTIBODIES THERETO | NEW YORK UNIVERSITY (US) | 1995-08-03 | — | — | WO | disclosed |
| WO-1995013828-A1 | BENEFICIAL WOUND HEALING APPLICATIONS OF CALRETICULIN AND OTHER HYALURONAN-ASSOCIATED PROTEINS | NEW YORK UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013291-A1 | NEURON-GLIA CELL ADHESION MOLECULE, NG-CAM, IN TREATMENT OF NERVE DAMAGE | NEW YORK UNIVERSITY (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1994005695-A9 | POLYPEPTIDES OF G-COUPLED RECEPTOR PROTEINS, AND COMPOSITIONS AND METHODS THEREOF | — | 1994-05-11 | — | — | WO | disclosed |
| WO-1994003601-A9 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | — | 1994-03-31 | — | — | WO | disclosed |
| WO-1994005695-A1 | POLYPEPTIDES OF G-COUPLED RECEPTOR PROTEINS, AND COMPOSITIONS AND METHODS THEREOF | NEW YORK UNIVERSITY (US) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994003601-A2 | CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN | NEW YORK UNIVERSITY (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062449-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | HGFAC, VIP, ARGLU1 | ACE 4586/4885MMP1 1706/4885MMP8 2886/4885 |
| US-20260049106-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE | ARGLU1, HGFAC, VIP | ACE 4747/4885MMP1 2200/4885MMP8 3457/4885 |
| US-20260034223-A1 | BIOMIMETIC EXTRACELLULAR MATRIX NANOFIBERS ELECTROSPUN WITH CALRETICULIN | CALR, ERP44, PDIA4 | ACE 3101/4885MMP1 172/4885MMP8 1235/4885 |
| US-12617818-B2 | Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them | MYLK2, TNNC1, MYOF | ACE 2643/4885MMP1 3728/4885MMP8 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.